Today's life science landscape is characterized by a much more commercial view of biotechnology than in the past, with intellectual property concerns and commercial rights attached to virtually every piece of work. The increasing awareness of potential public health risks from the transport and use of biological materials has resulted in regulatory constraints that must be negotiated to engage in productive R&D.